Topics:
Gastrointestinal Cancers • Medical Oncology • NCI-CCC Tumor Board Question • Rutgers • NCI-CCC GI Tumor Board Question • Hepatocellular Carcinoma
What is your preferred second line therapy for an HCC patient who progressed after first line checkpoint inhibitor monotherapy?
Would you try atezolizumab/bevacizumab or switch to a TKI?
Answer from: Medical Oncologist at Community Practice
After progression on immunotherapy monotherapy, assuming the patient is still eligible for further therapy and VEGF inhibition, I will move to a VEGF TKI. While the data supports the use of lenvatinib or sorafenib in the front-line setting (REFLECT and SHARP trials), I will use one of these agents (...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
This is a great question as the sequencing of treatment in HCC has drastically changed following the approval of atezolizumab/bevacizumab in the front line setting. For patients who have progressed on single agent immune checkpoint inhibitor in the front line setting, I would consider atezolizu...
Comments
Medical Oncologist at NYU Grossman School of Medicine
This is how I was leaning - a trial of the doublet...
This is how I was leaning - a trial of the doublet...